Sentences with phrase «leading drug candidate»

A leading drug candidate has more funding and is further advanced, but it also faces obstacles.

United Therapeutics will pay $ 4.46 per share in cash at closing yesterday and an additional $ 2.63 per share in cash upon the achievement of a milestone related to the commercialization of SteadyMed's leading drug candidate Trevyent for the treatment of Pulmonary Arterial Hypertension (PAH).

Zymeworks will be putting its two leading drug candidates, both targeted at breast cancer, into clinical trials in the next few months.

That's particularly unfortuante for Cerecor seeing as CERC - 501 is the company's lead drug candidate — and the news comes just days after Cerecor announced that a separate experimental depression drug called CERC - 301 had also failed in the clinic.

After shares got crushed yesterday over safety concerns for its lead drug candidate, shares of Esperion Therapeutics (NASDAQ: ESPR) were down another 22 % at 12:30 p.m. EDT today following a J.P. Morgan downgrade.

Blueprint Medicines (BPMC)- The current $ 3.75 billion valuation compares favorably to $ 2 billion peak sales potential of two lead drug candidates, while their solid cash position after the December secondary offering and their deep pipeline provide adequate cushion to the current share price.

George Budwell (Trevena): The clinical - stage biotech Trevena is set to release top - line results from two phase 3 studies (APOLLO - 1 and APOLLO - 2) for its lead drug candidate, oliceridine, in the first quarter of 2017.

Zucara Therapeutics Secures US$ 3.9 M from the Helmsley Charitable Trust to Advance Diabetes Lead Drug Candidate to Clinical Trials

NeuroPhage's lead drug candidate, NPT088, is a fusion protein combining a GAIM motif with a portion of a human antibody.

As potential lead drug candidates, we generated a large number of derivatives of the curry spice curcumin, which is effective in AD transgenic mice [8, 9].

One injection of EDP's lead drug candidate, SIA - II insulin has demonstrated tight glucose control for 140 + days in established diabetic animal models.

Not exact matches

The company's lead candidate is Trevyent, a development stage drug product that utilizes SteadyMed's PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension.

I've owned it for the past three years with a cost average of $ 4.64 - it's the future of cancer treatment in my opinion, with brain cancer patients living 7 plus years on its lead drug and impressive results in its second drug candidate for triple negative breast cancer.

Given the clinical trial results underpinning a new drug application for Kite Pharma's lead candidate, which the Food and Drug Administration is currently reviewing, I'd say there's a solid chance Gilead can squeeze out a return on its investmdrug application for Kite Pharma's lead candidate, which the Food and Drug Administration is currently reviewing, I'd say there's a solid chance Gilead can squeeze out a return on its investmDrug Administration is currently reviewing, I'd say there's a solid chance Gilead can squeeze out a return on its investment.

«Yet here we are in 2015 and a leading candidate for the GOP nomination for president is calling Mexicans criminals, rapists and drug dealers,» the letter states.

Two years ago the pharmaceutical giant GlaxoSmithKline purchased Sirtris for $ 720 million, and by August of last year The New York Times was speculating that compounds capable of activating sirtuin genes were now the leading candidates for what the newspaper called «the ultimate free lunch... a drug that tricks the body into thinking it is on [a calorie - restricted] diet.»

Several years ago, for example, poor chemical probe data led researchers to pursue a final stage clinical trial on a cancer drug candidate called iniparib.

The initiative is great because it has three components: it leads to an increased understanding of resistance mechanisms, brings new candidate drugs forward, and provides a way to share data, including about what does not work.»

Efforts aimed at finding better drug regimens would therefore greatly benefit from a mouse model with an intrinsic marker that can indicate different stages of pancreatic tumor formation leading to cancer and reflect the effects exerted by novel drug candidates.

«We believe this way of examining drug evidence could be expanded upon for use in public health surveillance and monitoring in other regions,» said lead author Kathleen Creppage, M.P.H., C.P.H., a doctoral candidate in Pitt Public Health's Department of Epidemiology.

«Now, because we know the resistance mechanism, we can design elements to minimize the emergence of resistance as these promising new drug candidates are developed,» said Ben Shen, a TSRI professor who led the study, which was published February 20, 2014 online ahead of print by the Cell Press journal Chemistry & Biology.

In a development that could lead to a new generation of drugs to precisely treat a range of diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time designed a drug candidate that decreases the growth of tumor cells in animal models in one of the hardest to treat cancers — triple negative breast cancer.

This has led to a demand for people who can understand data collection techniques and analyze vast amounts of data, categorize the data sets, develop models to test hypotheses that can then be used to develop drugs, and test potential candidates in animals.

This could to lead to stronger and more selective drug candidates, while lower amounts would be needed to trigger the desired effect.»

«Instead of pursuing leads, which is the traditional method, SuFEx click chemistry is about connecting promising drug candidates directly with targets,» says Sharpless.

For example, Novartis and the University of Pennsylvania's lead candidate (CTL019) for treating a range of hematological malignancies received breakthrough status from the US Food and Drug Administration (FDA) in 2014, permitting access to an expedited drug development pathway for high unmet medical needs Drug Administration (FDA) in 2014, permitting access to an expedited drug development pathway for high unmet medical needs drug development pathway for high unmet medical needs (1).

An alternative approach, most common for anti-infectives, is to use compounds («phenotypic inhibitors») which have already been shown to be active against the target organism in the living pathogenic cell as chemical leads for improvement by Medicinal Chemistry, towards systemically active Candidate Drugs.

The drug candidate has a huge potential market: cardiovascular disease is the world's leading killer, taking the lives of 17.5 million people annually worldwide and disabling millions more.

This can help identify new molecules likely to inhibit certain therapeutic targets and to lead to novel drug candidates.

It helps us understand the genetic basis of diversity and evolutions in organisms, leading to the insight understanding into how living things evolved through stressed environments to the pathogenesis of pathogens, including identification novel drug targets and development of novel drug candidates.

Our industry - leading technology, invented by GigaGen's co-founders, interrogates immune systems with unprecedented depth and breadth — radically accelerating the selection of drug targets, identification of drug candidates and assessment of pre-clinical drug efficacy.

Yin noted that with a better understanding of the genetic underpinnings that lead to tissue regeneration, he and his team may be able to develop new drug candidates that control the activity of the genetic circuits and repair damaged hearts.

The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer's disease.

Their contributions to the yeast community include physical mapping methods, synthetic lethality screen approaches for identifying cross-species candidate genes as potential cancer drug targets, and a widely used set of vectors and yeast host strains that have been instrumental in work that has led to countless discoveries in recent decades.

Chicago, Ill., July 20, 2016 — AveXis, Inc., a clinical - stage gene therapy company developing treatments for patients suffering from rare and life - threatening neurological genetic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for AVXS - 101, the company's lead development candidate for the treatment of spinal muscular atrophy (SMA) Type 1 in pediatric patients.

Cancer Research Technology will lead drug discovery R&D activity and can progress clinical candidates through phase one trials.

BOSTON, Mass. — Emulate, Inc. announced today that it has formed a strategic partnership with F Hoffman La - Roche AG (Roche) that will use Emulate's Human Emulation System across R&D programs to enable more human - relevant studies that will lead to earlier and better prediction of safety and efficacy of drug candidates.

Committed to supporting research with the highest probability of advancing potential drug candidates, the SMA Foundation has forged collaborations with leading medical institutions and industry in the United States and internationally.

For example, Novartis and the University of Pennsylvania's lead candidate (CTL019) for treating a range of hematological malignancies received breakthrough status from the US Food and Drug Administration (FDA) in 2014, permitting access to an expedited drug development pathway for high unmet medical neDrug Administration (FDA) in 2014, permitting access to an expedited drug development pathway for high unmet medical nedrug development pathway for high unmet medical needs.

The journal covers the whole of the preclinical drug discovery process, from target identification and validation, through hit identification, lead identification and optimisation, though to candidate selection.

The journal covers the whole of the preclinical drug discovery process, from target identification and validation, through hit identification, lead identification and optimisation, though to candidate selection.

The journal covers the whole of the preclinical drug discovery process, from target identification and validation, through hit identification, lead identification and optimisation, though to candidate selection.